Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?
deadline 2027-05-30
confidence medium
tier 4 evidence
52%PolySignal estimate
Resolution criterion
Yes if, when NCT06360133 is read on clinicaltrials.gov on 30 May 2027, the exact API field protocolSection.statusModule.completionDateStruct.date — Study Completion Date is 30 April 2027 or earlier — that is, the date announced today has not been pushed back. A later recorded date counts as no. If OverallStatus is Terminated, Withdrawn, Suspended, or Unknown status, that counts as no — an unmaintained or halted record is treated as a failure to hold the date, not as a technicality. The value returned by the ClinicalTrials.gov API on the deadline prevails; where the record gives a month without a day, the last day of that month is used. If that exact field is absent or empty on an otherwise existing record, that also counts as no – a missing date is not evidence the deadline will be met, it is treated the same as a halted record.
Verified starting state
As of 6 October 2026: NCT06360133 is registered as RECRUITING, sponsored by VivaVision Biotech, Inc, with 700 participants. Started 2024-04; announced primary completion 2027-04-30, announced study completion 2027-04-30. Record last updated 2026-08-20. The date under test is 2027-04-30. Source: clinicaltrials.gov/study/NCT06360133
What pushes it up
- The study record was updated as recently as August 20, 2026, which reaffirmed the April 30, 2027, completion date [1].
- The trial is currently in the 'Recruiting' phase, indicating active progress toward the participant goal [1].
What pushes it down
- Large-scale trials with 700 participants are highly susceptible to recruitment bottlenecks that often necessitate timeline extensions [1].
- The resolution criteria are strict: any shift to 'Unknown', 'Suspended', or 'Terminated' status results in a 'No' resolution [1].
- Biotech sponsors often face more resource constraints than major pharmaceutical firms, increasing the risk of schedule slippage.
What would move this number most
The current enrollment progress relative to the 700-participant target; if recruitment is not nearly complete by late 2026, the April 2027 date is unlikely to hold.
How this number is built
| Deadline | 2027-05-30 |
| Base rate | 45% |
| Best evidence | tier 4 · 0 article(s) used |
| Independent runs | 35 · 52 · 55 (spread 20 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-06 09:08 |
| Model | gemini-3-flash-preview |